{"filings":[{"id":982677,"accession_number":"0000818479-26-000200","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2026-06-11T12:32:06+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Dentsply Sirona appoints John Fortson as EVP & CFO; base salary $780K","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Fortson named EVP & CFO effective July 20, 2026; previously CFO at Kymera International and CEO at Ingevity.","Compensation includes $780K base salary, 85% target bonus, $500K sign-on cash (Feb 2027), and $700K sign-on equity.","Sign-on equity 60% premium stock options, 40% RSUs, three-year ratable vesting.","Employment subject to severance plans and two-year non-compete agreement.","Fortson brings 25+ years of finance and operations leadership experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":861639,"accession_number":"0000818479-26-000165","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2026-06-04T20:23:44+00:00","items":["5.07"],"status":"ready","headline":"Dentsply Sirona shareholders elect 12 directors and approve 15M share equity plan increase","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 12 director nominees elected; Donald J. Zurbay received 51.1M votes against (30.4% of cast), highest opposition.","Ratification of Deloitte & Touche as 2026 auditor passed with 99.7% of votes cast in favor.","Non-binding advisory vote on 2025 executive compensation passed with 94.5% support (excluding broker non-votes).","Amendment to 2024 Omnibus Incentive Plan approved to add 15M shares; 83.4% of votes cast in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99040,"accession_number":"0000818479-26-000147","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dentsply Sirona Q1 adj EPS $0.27, down 39% YoY; net sales flat at $880M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss per share ($0.05); adjusted EPS $0.27 vs $0.44 in Q1 2025.","Net sales $880M (+0.1% as reported); constant currency sales declined 6.7% YoY.","GAAP gross margin 48.5% vs 53.0% a year ago; adjusted EBITDA margin 14.7% vs 19.0%.","Orthodontic & Implant Solutions sales down 8.1% as reported; Wellspect Healthcare up 15%.","Reiterated 2026 outlook: net sales $3.5B-$3.6B, adj EPS $1.40-$1.50."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":880000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114835,"accession_number":"0000818479-26-000072","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dentsply Sirona Q4 net loss $146M on $144M impairments; eliminates dividend, guides FY2026 adj EPS $1.40-$1.50","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $961M (+6.2% reported, +2.5% constant currency); reported diluted EPS ($0.74) from $144M impairments.","FY2025 net sales $3.68B (-3.0%), adjusted EPS $1.60. FY2026 guidance: sales $3.5-3.6B, adjusted EPS $1.40-1.50.","Restructuring plan approved: $55-65M charges, ~$120M annual savings, reinvested in growth initiatives.","Quarterly dividend eliminated; capital redeployed to debt retirement and share repurchases.","Appointed three new board members (Forbes, McKeon, Zurbay); new distribution agreements with Patterson, Benco, Burkhart, A-dec."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":3680000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114834,"accession_number":"0000818479-26-000058","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Dentsply Sirona appoints Forbes and McKeon to board; Deese retiring","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Forbes (former Morgan Stanley vice chairman) and Brian McKeon (former IDEXX CFO) join Board effective Feb 27, 2026.","Forbes will serve on Compensation & Human Capital Committee; McKeon on Audit/Finance and Science/Technology Committees.","Board size increased from 11 to 13 as part of ongoing refreshment to support Return-to-Growth plan.","Willie Deese will not stand for re-election at 2026 annual meeting; no disagreement with company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114833,"accession_number":"0000818479-26-000043","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Dentsply Sirona renews U.S. dental technology distribution agreement with Patterson Dental","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Renewed non-exclusive agreement covers Dentsply Sirona's full portfolio including CEREC, Primescan, Axeos, and Orthophos systems.","Partnership aims to accelerate adoption of integrated technologies and expand access to dental professionals across the U.S.","Quotes from Dentsply Sirona CCO Aldo Denti and Patterson Dental President Patrik Eriksson highlight commitment to growth and innovation.","Agreement effective January 14, 2026; underscores decades-long collaboration between the two companies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114832,"accession_number":"0000818479-26-000024","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Dentsply Sirona adds former Patterson CEO Zurbay to Board; creates Growth and Value Creation Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Donald Zurbay appointed to Board effective Jan 10, 2026; former Patterson CEO/CFO and St. Jude Medical CFO.","Board expanded from 10 to 11 members; Zurbay joins Audit and Finance Committee.","Board established Growth and Value Creation Committee to oversee Return-to-Growth action plan, co-chaired by Chairman & CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131221,"accession_number":"0000818479-25-000300","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Dentsply Sirona amends debt covenants; new leverage ratios step down to 3.50x, restricts dividends","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New Total Leverage Ratio covenant: cannot exceed 4.25x (Q4 2025–Q2 2026) stepping down to 3.50x (Q3 2027+).","New Senior Leverage Ratio covenant: cannot exceed 3.25x (same period) stepping down to 2.50x (Q3 2027+).","Restricted Payments (dividends, buybacks) prohibited subject to specified exceptions.","EBITDA addback cap for efficiency initiatives: up to $75M aggregate for Q4 2025 through Q4 2026.","Interest rate adjustments triggered if total leverage ratio exceeds specified thresholds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131220,"accession_number":"0000818479-25-000281","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"DENTSPLY SIRONA appoints Michael Pomeroy as interim CFO; CEO remains principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Pomeroy appointed interim CFO effective November 25, 2025.","CEO Daniel Scavilla will continue as principal financial officer until a permanent CFO is named.","Pomeroy most recently served as interim CFO of Highridge Medical (Feb-Sep 2025).","Prior roles include EVP and CFO of Icahn Automotive Group (2022-2024) and VP/CFO of RGIS.","Permanent CFO search is ongoing; Pomeroy's appointment is temporary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131215,"accession_number":"0000818479-25-000267","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K/A","filed_at":"2025-11-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CFO Matthew Garth separation agreement: $1.2M in payments, equity forfeiture, restrictive covenants","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matthew E. Garth's separation effective Nov 5, 2025; agreement signed Nov 7, 2025.","Severance: $1.2M in two $600k installments plus $32,430 for COBRA premiums.","Unvested equity awards forfeited except prorated portion (5/36ths) of May 30, 2025 PRSUs.","Receipt of payments contingent on release and compliance with restrictive covenants.","Outplacement services for 12 months provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131219,"accession_number":"0000818479-25-000254","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dentsply Sirona Q3 net sales down 5% to $904M; GAAP loss $2.14/share; cuts FY25 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $904M, down 5.0% as-reported, 8.0% constant currency; GAAP net loss per share ($2.14).","Adjusted EPS $0.37 vs $0.50 prior year, down 26.5%; adjusted gross margin 52.6% from 55.3%.","CFO Matt Garth departed; Aldo Denti named Chief Commercial Officer; Dustin Shields named Chief Transformation Officer Dec 1.","FY25 revised outlook: net sales $3.6B-$3.7B, constant currency decline 4%-5%, adjusted EPS ~$1.60.","Q3 goodwill impairment charge $263M net of tax ($1.31 per share)."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":2719000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131218,"accession_number":"0000818479-25-000253","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Matthew Garth to depart Nov 5; CEO Scavilla takes interim CFO role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matthew E. Garth will leave as EVP and CFO effective November 5, 2025.","Departure not due to any disagreement on financial statements, controls, or operations.","Company has initiated a formal search process for a new CFO.","CEO Daniel T. Scavilla appointed interim principal financial officer for SEC filings.","No new compensatory arrangements entered for Scavilla in connection with interim role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131217,"accession_number":"0000818479-25-000203","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SEC concludes investigation of Dentsply Sirona without enforcement action","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["SEC's Division of Enforcement closed its investigation initiated May 2022.","No enforcement action recommended; company fully cooperated throughout.","Investigation related to financial reporting allegations from current/former employees.","Company views closure as a significant and favorable development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131216,"accession_number":"0000818479-25-000182","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"EVP, General Counsel & Secretary Richard Rosenzweig departs; becomes Special Legal Advisor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard C. Rosenzweig ceases role as EVP, Corporate Development, General Counsel and Secretary effective Oct 3, 2025 by mutual agreement.","Rosenzweig transitions to non-officer Special Legal Advisor through March 4, 2026 with monthly fixed fee of $30,000.","Eligible for severance: $606,320 base salary, $454,740 target bonus, $32,309 COBRA, 2025 bonus, and accelerated vesting of one-time RSU grant.","After separation, will serve as independent contractor consultant for one year at $20,000/month.","Receives full 100% vesting of SERP deferred compensation; non-compete period begins Oct 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147810,"accession_number":"0000818479-25-000174","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Dentsply Sirona awards $2M retention stock options to SVP/Chief Supply Chain Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Retention grant of stock options with grant-date fair value of $2,000,000 to Tony Johnson, SVP and Chief Supply Chain Officer.","Options cliff-vest on third anniversary of grant date, subject to continuous employment.","Half of options priced at fair market value (FMV) on grant date; half at 110% of FMV.","Grant expected on second trading day after Q3 2025 10-Q filing; expires 10 years from grant date.","Award intended to retain Johnson following recent CEO/CFO transition and recognize his performance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147809,"accession_number":"0000818479-25-000167","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Dentsply Sirona Retains Wellspect Healthcare After Strategic Review, Ends Sale Process","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Strategic review of Wellspect begun Feb 2025 completed Sep 8, 2025; company decided to retain the business.","Wellspect is a leader in continence care with LoFric and Navina brands; mid-single digit organic sales growth in 2024.","CEO Dan Scavilla cited strong cash flow, untapped market potential, and a $2B addressable market for the decision.","Company conducted broad outreach and considered a sale but determined retention creates more stockholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147808,"accession_number":"0000818479-25-000152","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dentsply Sirona Q2 net sales $936M (-4.9%); adjusted EPS $0.52 (+6.6%); appoints new CEO Dan Scavilla","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $936M, down 4.9% (down 6.7% constant currency); GAAP net loss ($45M) or ($0.22) per share.","Adjusted EPS $0.52 vs $0.49; adjusted EBITDA margin 21.1% vs 17.5% (14.6% growth).","Executed $550M debt offering; reaffirmed FY25 outlook.","Dan Scavilla appointed CEO effective Aug 1, 2025; Matt Garth as CFO effective May 30, 2025.","Byte sales had a 3.2% negative impact on constant currency sales."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":1815000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147807,"accession_number":"0000818479-25-000137","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Dentsply Sirona appoints Daniel Scavilla as CEO; preliminary Q2 sales ~$935M and adj. EPS $0.50-0.52","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel Scavilla appointed President & CEO effective Aug 1, 2025, succeeding Simon Campion who departs July 31, 2025.","Preliminary Q2 net sales ~$935M and adjusted EPS expected between $0.50 and $0.52.","Company reaffirms 2025 outlook provided in May 8 earnings release.","Campion to receive severance per existing agreement, including SERP vesting and up to $90k in relocation/legal reimbursements.","Scavilla receives base salary $1.03M, target bonus 135%, initial equity grant ~$6.4M, and signing bonuses up to $1.75M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166509,"accession_number":"0001193125-25-140055","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Dentsply Sirona issues $550M of 8.375% junior subordinated notes due 2055, repays $435M bridge loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $550M aggregate principal of 8.375% Fixed-to-Fixed Reset Rate Junior Subordinated Notes due September 12, 2055.","Interest rate: 8.375% through September 12, 2030, then resets to 5-year UST rate + 4.379% with an 8.375% floor.","Used proceeds to repay in full the outstanding $435M 364-day bridge loan facility, terminating it with no penalties.","Notes redeemable at par during 90 days before first reset date and on interest payment dates after first reset."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166508,"accession_number":"0001193125-25-136361","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Dentsply Sirona prices $550M 8.375% junior subordinated notes due 2055","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$550M aggregate principal amount of 8.375% fixed-to-fixed reset rate junior subordinated notes due 2055.","Net proceeds ~$544.5M; expected close June 12, 2025, subject to customary conditions.","Interest fixed at 8.375% until Sep 12, 2030, then resets at 5yr UST + 4.379% with 8.375% floor.","Proceeds to repay existing $435M term loan and other short-term debt; general corporate uses.","Goldman Sachs sole book-runner; PNC, Commerz Markets, Truist, MUFG acting as co-managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166507,"accession_number":"0001193125-25-134427","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Dentsply Sirona amends credit agreements to add leverage covenant, increase ratio limit to 65%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New financial covenant: senior debt to capitalization must not exceed 60%.","Maximum allowable consolidated leverage ratio increased to 65%.","German subsidiary debt reclassified as permitted debt under a standalone basket.","Interest rate adjustments triggered if credit rating falls below investment grade.","Amendments affect revolving credit facility and three note purchase agreements; effective upon satisfaction of conditions precedent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166506,"accession_number":"0000818479-25-000086","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Dentsply Sirona appoints Matthew Garth as CFO, effective May 30, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matthew Garth named EVP & CFO; previously CFO & CAO of Scotts Miracle-Gro.","Compensation: $800k base salary, 85% target bonus, annual equity grant of $2.75M.","Equity components: stock options ($687.5k), RSUs ($687.5k), PRSUs ($1.375M) with 3-year targets.","Nearly 30 years of financial leadership at Scotts, Minerals Technologies, and Alcoa.","No family relationships or material transactions disclosed; subject to non-compete and severance plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166505,"accession_number":"0000818479-25-000080","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"DENTSPLY SIRONA annual meeting elects all 11 directors; approves 11.26M share increase for incentive plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected with >94% of votes cast; broker non-votes of ~11.3 million.","Ratification of Deloitte as auditor for 2025: 187.6 million for, 0.4 million against.","Non-binding advisory vote on 2024 executive compensation approved: 170.9 million for, 4.9 million against.","Amendment to 2024 Omnibus Incentive Plan to increase shares by 11.26 million approved: 166.0 million for, 10.6 million against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166504,"accession_number":"0000818479-25-000053","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Dentsply Sirona Q1 net sales -7.7%; CFO Cueto departs, CEO Campion as interim PFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $879M (-7.7% YoY); organic sales -4.4% including -4.0% Byte impact.","GAAP EPS $0.10; adjusted EPS $0.43 vs $0.42 YoY; adjusted EBITDA margin 19.0% (16.8% prior year).","Maintaining FY25 outlook for organic sales and adjusted EPS; raising reported sales forecast from F/X.","Herman V. Cueto completed interim CFO assignment; CEO Simon Campion serves as principal financial officer until permanent CFO appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":879000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183934,"accession_number":"0000818479-25-000042","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Dentsply Sirona enters $435M bridge loan agreement, borrows full amount to repay commercial paper","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Bridge loan facility of $435M, 364-day maturity, borrowed in full at closing on March 19, 2025.","Proceeds to repay outstanding commercial paper and for general corporate purposes.","Interest rate: Term SOFR plus 0.875%-1.375% margin based on credit rating, with step-ups after 90, 180, and 270 days.","Duration fees of 0.50%, 0.75%, and 1.00% payable if principal remains outstanding after 90, 180, and 270 days.","Covenants include leverage and interest coverage ratios; mandatory prepayment on debt/equity issuances or asset sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183933,"accession_number":"0000818479-25-000030","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dentsply Sirona Reports FY 2024 Net Sales of $3,793M, Net Loss of $910M, and Provides 2025 Outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY24 net sales decreased 4.3% to $3,793M; organic sales down 3.5% including a 1.2% Byte sales impact.","FY24 GAAP net loss of $910M or $4.48 per share, compared to net loss of $132M in 2023.","Q4 net sales decreased 10.6% to $905M; GAAP net loss of $430M or $2.16 per share.","Non-cash impairment charges of $870M net of tax in FY24, $370M in Q4.","FY25 outlook: net sales $3.50B to $3.60B, adjusted EPS $1.80 to $2.00."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":3793000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183932,"accession_number":"0000818479-25-000018","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Dentsply Sirona starts strategic review for Wellspect Healthcare unit","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Wellspect provides bladder/bowel care products (LoFric, Navina); $2B TAM.","Mid-to-high single-digit organic sales growth in 2023 and first 3Q of 2024.","Goldman Sachs & Co. LLC (financial) and Wachtell Lipton (legal) retained as advisors.","No deadline or assurance that a transaction will result from the review.","Q4 & full-year 2024 results to be reported on February 27, 2025 as planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183931,"accession_number":"0000818479-25-000013","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Dentsply Sirona appoints Michael Barber and Daniel Scavilla to board; Dorothea Wenzel resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 10 to 11 members; appointments effective February 5, 2025.","Michael Barber (former GE exec, 40+ years product management) joins Science and Technology Committee.","Daniel Scavilla (CEO of Globus Medical, led NuVasive merger) joins Audit and Finance Committee.","Dorothea Wenzel resigned effective Feb 5, 2025, citing increased demands of chair nomination; no disagreement.","Board has added four new members in last two years as part of refresh to support transformation strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183930,"accession_number":"0000818479-25-000005","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Dentsply Sirona discontinues at-home Byte aligner kits, expects Q4 refunds and asset write-offs","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Byte at-home aligner systems and impression kits discontinued; focus shifts to in-person dentist oversight.","Company expects material Q4 2024 charges for customer refunds and potential asset write-offs.","Existing non-contraindicated Byte patients will continue to receive support during treatment.","Repositioning leverages Byte's direct-to-consumer capabilities across the aligner portfolio and company.","Dentsply Sirona will present Byte update at J.P. Morgan Healthcare Conference on Jan 15, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200529,"accession_number":"0000818479-24-000099","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"German criminal probe into Dentsply Sirona's 2016-2017 loans; interim CFO named","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["German authorities searched Company sites in Bensheim and Hanau on Nov 7, 2024 as part of criminal investigation into post-merger intercompany loans.","Investigation examines arm's length structuring and interest deductibility for tax years 2016-2017; no charges filed.","Company intends to fully cooperate and assert its positions, including pursuing appeals as necessary.","Appointed Herman V. Cueto as interim CFO, effective immediately; he previously served as CFO of Azenta Life Sciences.","CEO Simon Campion continues as principal financial officer until permanent CFO is appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200528,"accession_number":"0000818479-24-000086","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Dentsply Sirona Q3 GAAP loss of $494M, cuts FY24 outlook; CFO transition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $494M ($2.46/sh) vs $266M loss a year ago; includes $495M goodwill impairment.","Adjusted EPS $0.50 vs $0.49; organic sales +1.3% aided by ~$20M stocking orders.","FY24 outlook lowered: organic sales now (3.5%)–(2.5%); adjusted EPS $1.82–$1.86.","Kevin Czerney appointed CAO; CEO Simon Campion as interim CFO on Nov 7 after Glenn Coleman resigns."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":2888000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200527,"accession_number":"0000818479-24-000076","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Dentsply Sirona suspends Byte aligner sales after FDA consult; Q3 rev ~$951M, impairment up to $550M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Voluntarily suspends sale/marketing of Byte aligners and impression kits in consultation with FDA.","Byte represents ~5% of annual revenue; suspension expected to materially impact operations.","Prelim Q3 net sales ~$951M; adjusted EPS guided $0.49-$0.51 (non-GAAP).","Expects $450-$550M non-cash goodwill impairment (net of tax) for Orthodontic Aligner and Implant reporting units.","Q3 sales benefited by ~$20M shift of distributor orders from Q4 due to ERP implementation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216544,"accession_number":"0000818479-24-000072","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Dentsply Sirona CFO Glenn Coleman resigns effective Nov 7, 2024; search underway","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Glenn Coleman resigned as EVP, CFO effective Nov 7, 2024, to join another public company.","Resignation not due to any disagreement with the company on financial statements, controls, or policies.","Company has initiated a formal search for a new CFO with assistance from an executive search firm.","CEO Simon Campion thanked Coleman for contributions to business transformation, ERP modernization, and Employee Resource Groups."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216543,"accession_number":"0000818479-24-000070","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","2.05","5.02","7.01","9.01"],"status":"ready","headline":"Dentsply Sirona Q2 net loss $4M, lowers FY24 outlook, begins restructuring","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $984M (-4.2% YoY), organic sales -2.3%; GAAP net loss $4M ($0.02/share), adjusted EPS $0.49 vs $0.51.","FY24 outlook cut: organic sales now -1% to 0% (prev. flat to +1.5%), adjusted EPS $1.96-$2.02 (prev. $2.00-$2.10).","Restructuring: $40-$50M charges (employee severance), $80-$100M annual savings, 2-4% workforce reduction, complete by end 2025.","EVP Chief Business Officer Frank to leave Oct 1; CAO Wagner resigns Aug 16; CFO Coleman interim CAO.","Repurchased $150M stock in Q2, plans $100M repurchase in Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":1937000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236191,"accession_number":"0000818479-24-000044","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"All 10 Dentsply Sirona director nominees elected; compensation plans approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 10 director nominees elected with 95-99% support; highest vote-getter Dorothea Wenzel at 184.4M for.","Ratification of Deloitte as auditor approved with 192.6M for (99.4% of votes cast).","Non-binding say-on-pay passed with 178.9M for (96.7% of votes cast excluding broker non-votes).","2024 Omnibus Incentive Plan approved with 174.8M for; Amended ESPP approved with 184.2M for.","Broker non-votes present on director elections and advisory compensation vote (8.7M shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236190,"accession_number":"0000818479-24-000033","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dentsply Sirona Q1 net sales $953M (-2.6%); adj. EPS $0.42, up 7.9% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales of $953M declined 2.6% YoY; organic sales down 1.9%.","GAAP net income of $18M ($0.09 EPS) vs. net loss of $19M ($0.09 loss) in Q1 2023.","Adjusted EPS of $0.42, up from $0.39 in Q1 2023; adjusted EBITDA margin 16.8%.","Maintaining FY24 outlook, trending toward low-end of organic sales and adjusted EPS ranges.","Announced up to $150M share repurchase planned in Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":953000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253892,"accession_number":"0000818479-24-000026","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Dentsply Sirona replaces PwC with Deloitte as auditor for FY2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dismissed PwC on March 4, 2024; appointed Deloitte as new independent auditor for FY2024.","No adverse opinions or disagreements with PwC for FY2022 and FY2023 audits.","Prior material weaknesses in internal controls (manual journal entries, tone at top, incentive arrangements) fully remediated as of Dec 31, 2023.","Deloitte engagement subject to customary client acceptance procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253891,"accession_number":"0000818479-24-000017","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Dentsply Sirona director Eric K. Brandt to retire at May 2024 annual meeting after nearly 20 years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric K. Brandt, director for nearly 20 years and Chairman for 6 years, will not stand for re-election at May 2024 annual meeting.","Retirement decision is not the result of any disagreement with the company.","Non-Executive Chairman Gregory T. Lucier expressed gratitude for Brandt's service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253890,"accession_number":"0000818479-24-000015","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dentsply Sirona Q4 adj EPS $0.44, FY23 adj EPS $1.83; FY24 outlook adj EPS $2.00-$2.10","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY23 net sales $3,965M (+1.1% YoY), organic +2.2%; GAAP net loss $132M ($0.62/share).","Q4 net sales $1,012M (+2.9% YoY), GAAP net income $67M ($0.32/share), adjusted EPS $0.44.","FY23 adjusted EPS $1.83 vs $2.09 in FY22; Q4 adjusted EBITDA margin 17.1% vs 17.5% a year ago.","FY24 guidance: organic sales flat to +1.5%, adjusted EPS $2.00-$2.10, implying YoY improvement.","Company raised its dividend (specific amount not detailed in release)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":3965000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253889,"accession_number":"0000818479-24-000004","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Dentsply Sirona expects FY2023 sales at or above $3.94B, reaffirms adj. EPS $1.80-$1.85","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary 2023 net sales expected at or above high end of prior $3.90-$3.94B range.","Adjusted EPS guidance reaffirmed at $1.80-$1.85 for full year 2023.","Year-over-year sales growth in Essential Dental, Wellspect, Ortho/Implant; decline in Connected Tech.","Company reaffirms expectation for double-digit adjusted EPS growth in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":3965000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271339,"accession_number":"0000818479-23-000088","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Dentsply Sirona sets 2026 adjusted EPS target of $3.00; authorizes $1B buyback","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Company targets adjusted EPS of $3.00 in 2026 as part of three-year financial plan.","Board authorized an additional $1 billion share repurchase program.","Investor Day held at Charlotte HQ with executive presentations, live Q&A, and customer panels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271338,"accession_number":"0000818479-23-000081","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Dentsply Sirona Q3 net loss $266M; lowers FY23 guidance; appoints Brian Gladden to board","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales flat at $947M, organic sales -0.3%; GAAP net loss $266M ($1.25/share) including $302M impairment.","Adjusted EPS $0.49, up 19.6% YoY; adjusted EBITDA margin 18.2% vs 17.5% a year ago.","FY23 guidance lowered: organic sales growth to ~1% from ~3%; adjusted EPS to $1.80–$1.85 from $1.92–$2.02.","Brian Gladden appointed to Board effective Jan 1, 2024, replacing retiring director Harry Kraemer Jr.","Company plans $150M share repurchase in Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":2953000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271337,"accession_number":"0000818479-23-000077","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K/A","filed_at":"2023-10-02T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Dentsply Sirona board adopts annual advisory say-on-pay vote per shareholder preference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders at May 24, 2023 annual meeting selected every 1 year as preferred frequency for say-on-pay.","Board of Directors adopted resolution to hold annual non-binding advisory vote on named executive officer compensation.","Resolution effective immediately, aligning with shareholder advisory vote outcome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288202,"accession_number":"0000818479-23-000074","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2023-09-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Dentsply Sirona appoints Gregory T. Lucier as Chairman; Harry Kraemer to retire from Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric K. Brandt steps down as non-Executive Chairman after 6 years, rotates to Board member and Corporate Governance/Nominating Committee member.","Gregory T. Lucier appointed Chairman of the Board and member of Corporate Governance and Nominating Committee, effective January 1, 2024.","Harry M. Jansen Kraemer, Jr., a director since 2006 (first with Sirona Dental Systems), retires effective December 31, 2023; no disagreement with the Company.","Lucier is CEO of Corza Health and former Chairman/CEO of Life Technologies and NuVasive; joined the Board in 2019."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288201,"accession_number":"0000818479-23-000067","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2023-09-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Dentsply Sirona settles with former CEO Casey; no additional payment, no clawback unless required by law","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement and release agreement dated Sept 10, 2023 with former CEO Donald M. Casey Jr., announced April 19, 2022.","No additional monetary consideration; Casey acknowledges he has already received all accrued obligations.","Company agrees not to seek clawback of compensation already paid unless required by regulatory agency, court order, or breach.","Company will facilitate indemnification and advancement of legal fees per February 2018 indemnification agreement.","Resolution removes potential litigation over Casey's separation and compensation recoupment policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288200,"accession_number":"0000818479-23-000052","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Dentsply Sirona Q2 organic sales +2.3%, raises FY guidance; discloses material weakness","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $1,028M (+0.5% reported, +2.3% organic); GAAP EPS $0.40, adj. EPS $0.51.","Raises FY23 net sales midpoint by $75M to $3.98-4.02B; adj. EPS outlook to $1.92-2.02.","Discloses new material weakness over manual journal entry segregation of duties as of Dec. 31, 2022.","Prior 10-K and Q1 10-Q internal control reports no longer reliable; financial statements unchanged.","Effective Q2 2023, reportable segments realigned to four: Connected Tech, Essential Dental, Ortho/Implant, Wellspect."],"consensus_eps_estimate":null,"consensus_eps_actual":0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":2006000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308652,"accession_number":"0000818479-23-000040","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2023-05-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Dentsply Sirona shareholders elect all 11 director nominees at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Eric K. Brandt received 171M votes for (88.3%) and 22.7M against; all other nominees received over 190M for votes.","Shareholders ratified PwC as auditor for 2023 with 194M for (97.1% of votes cast).","Say-on-pay proposal received 175.9M for (90.7% of votes cast), passing non-binding.","Advisory vote on frequency of executive compensation: one-year frequency approved with 189.7M for (97.8% of votes cast)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308651,"accession_number":"0000818479-23-000038","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Dentsply Sirona enters $700M revolving credit facility, extends maturity to 2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $700M five-year multicurrency revolving facility expires May 12, 2028, replacing existing $700M facility due July 2024.","Facility is senior unsecured; interest rates tied to Moody's/S&P ratings with spreads from 0% to 0.225% for ABR loans.","Covenants require leverage and interest coverage ratios consistent with prior facility; no change in financial covenant levels.","Proceeds for working capital and general corporate purposes; JPMorgan and Citibank lead arrangers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308650,"accession_number":"0000818479-23-000031","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dentsply Sirona Q1 net sales +0.9% to $978M, organic +5.1%; raises FY23 guidance low-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss of $19M ($0.09 loss per share) vs. $69M income ($0.32 EPS) in Q1 2022; includes $71M restructuring charges.","Adjusted EPS fell to $0.39 from $0.54; adjusted EBITDA $161M (16.4% margin) vs. $189M (19.6%) a year ago.","Raising low-end of FY23 net sales outlook by $50M, organic sales growth outlook by 100 bps, and adjusted EPS outlook by $0.05.","Growth driven by strong demand for aligners and consumables; CEO cites stable patient traffic and transformation momentum."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":978000000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308649,"accession_number":"0000818479-23-000026","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2023-04-12T23:59:59+00:00","items":["5.02","7.01"],"status":"ready","headline":"Director Groetelaars not seeking re-election; IDEXX CEO Mazelsky nominated to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director John P. Groetelaars will not stand for re-election at the 2023 Annual Meeting, ending his term.","Board approved Jonathan J. Mazelsky, President and CEO of IDEXX Laboratories, as a director nominee.","Groetelaars previously served as Interim CEO; Chairman Brandt thanked him for his service.","Mazelsky has been President and CEO of IDEXX since October 2019."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1951180000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-04-12T23:59:59+00:00|308649"}